While uncertainty remains high amid Trump's tariff blitz, Barclays analysts have highlighted six UK stock ideas for the ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

(Alliance News) - London stocks remained in the red at midday on Wednesday, as US tariffs continue to wreak havoc on global markets, and British gilt yields reach their highest point in more than 25 ...

Shares of major European drugmakers fell Wednesday morning after U.S. President Donald Trump reaffirmed plans to impose a ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Tuesday said Datroway has secured EU approval to treat breast cancer patients. Daiichi Sankyo, a Tokyo-based pharmaceutical company, and ...